Summary
Boston Scientific Corporation (BSX) has filed an 8-K report on January 9, 2018, to announce preliminary, unaudited sales results for the fourth quarter and full year ended December 31, 2017. This filing serves as an early communication of key financial performance indicators before the official earnings release. Investors should note that these results are preliminary and subject to revision as the company completes its standard financial closing procedures. The company provided a cautionary statement regarding forward-looking statements, emphasizing that actual results could differ materially from expectations due to various risks and uncertainties. These include, but are not limited to, economic conditions, competitive pressures, new product introductions, market acceptance, reimbursement issues, and clinical trial outcomes. Investors are advised to consider these factors when evaluating the preliminary sales figures.
Key Highlights
- 1Boston Scientific Corp (BSX) released preliminary unaudited sales results for Q4 and full-year 2017.
- 2The information was provided via a press release dated January 9, 2018, attached as Exhibit 99.1.
- 3The filed results are preliminary and subject to revision based on the company's standard financial closing processes.
- 4The company included a standard cautionary statement regarding forward-looking statements.
- 5Factors that could cause actual results to differ materially from preliminary estimates were outlined.
- 6Risks and uncertainties include market conditions, product acceptance, regulatory environments, and competitive factors.